Genentech cuts tape on melanoma combo trial

Roche's ($RHHBY) Genentech unit launched a new late-stage trial testing a two-drug combo in melanoma patients, throwing its hat in the ring with GlaxoSmithKline ($GSK), which is testing a rival combo therapy. Report

Suggested Articles

The future may be uncertain for AZ’s Imfinzi in first-line lung cancer, but its targeted med Tagrisso now boasts a green light in that setting.

Ultragenyx is back with another FDA nod, this time for Crysvita to treat X-linked hypophosphatemia in patients one year and older.

Roche got a two pieces of good Hemlibra news early this week—and what's good for Hemlibra must be good for Roche.